紫杉醇联合卡培他滨治疗进展期胃癌的临床观察

Study of paclitaxel combined capecitabine for advanced gastric cancer

目的：观察紫杉醇联合卡培他滨（希罗达）作为二线方案治疗晚期胃癌的有效性和安全性。方法：采用紫杉醇175mg／衍，静脉滴注3h，第1天；希罗达1000mg／m^2，每天2次，第1-14天，21天为1个周期，连用2个周期后评价疗效。结果：30例中，获得完全缓解（CR）2例，占6.7％；部分缓解（PR）12例，占40.0％；稳定（SD）11例，占36.7％；进展（PD）5例，占16.7％。总有效率（CR＋PR）为46.7％。不良反应主要为恶心呕吐、骨髓抑制、腹泻、手足综合征及脱发等。结论：紫杉醇联合卡培他滨二线治疗晚期胃癌疗效较高，安全性好。

Objective ： We evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as therapy in patients with advanced gastric cancer（AGC）. Methods：Patients with histologically confirmed unresectable or metastatic AGC were treated with eapecitabine 1000mg/m^2 p. o. twice daily on days 1-14 and paclitaxe1175mg/m^2 i. v. on day 1 every 3 weeks until disease progression or unacceptable toxicities . Resuhs：A total of 2 patients showed complete response and 12 showed partial response making the overall response rate 46.7%. Median time to progression was 6.7 months and median overall survival time was 9.9 months. Grade 3 or 4 adverse events include leukocytopenia, hand - foot syndrome, CINV ,and alopecia. There was no leukocytopenia fever or treatment - related deaths. Conclusion：Paclitaxel and capecitabine combination chemotherapy was active and highly tolerable as a therapy for AGC.